Sakar Healthcare working capital

·UnclassifiedChart ›

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

168.22×	168.22×	158.23×	94.07×	73.40×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
22.27×	22.27×	53.06×	51.16×	49.62×
107.49×	107.49×	107.64×	116.77×	140.43×
83.00×	83.00×	103.65×	28.46×	−17.41×
7.42×	8.14×	6.95×	12.22×	93.65×
0.56×	0.56×	0.44×	0.42×	0.44×
1.62×	1.62×	2.03×	2.10×	2.61×
0.72×	0.72×	0.72×	0.64×	1.01×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SAKAR₹946.50

Sakar Healthcare Limited

· Unclassified

₹ CrorePeersMACPOWER SERVOTECH KAPSTON THEJOBETAMcap ₹2,106 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Inventory Days (DIO)	73.40	94.07	158.23	168.22	168.22
Receivable Days (DSO)	49.62	51.16	53.06	22.27	22.27
Payable Days (DPO)	140.43	116.77	107.64	107.49	107.49
Cash Conversion Cycle (days)	-17.41	28.46	103.65	83.00	83.00
Working Capital Turnover	93.65	12.22	6.95	8.14	7.42
Asset Turnover	0.44	0.42	0.44	0.56	0.56
Cash Conversion (CFO/Net Income)	2.61	2.10	2.03	1.62	1.62
CFO/EBITDA	1.01	0.64	0.72	0.72	0.72

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.